Affordability – Talk Bio

ICER Draft Report: High-Cost GLP-1 Obesity Drugs Deemed Cost-Effective—Affordability Still a Concern

1 day ago talkbio0Tagged Affordability, cardiovascular benefits, Cost-Effectiveness, CREM gene, Glucagon-Like Peptide 1, Health Policy, Obesity, semaglutide, tirzepatide, value-based pricing

ICER; GLP-1; semaglutide; tirzepatide; obesity drugs; cost-effectiveness; health policy; affordability; value-based pricing; cardiovascular benefits

Lilly lowers price of Zepbound vials, launches new doses

7 months ago talkbio0Tagged Affordability, Dosage, Eli Lilly, Obesity, Prices

Eli Lilly, Dosage, Prices, Affordability, Obesity

Triple Threat: 50% of Women Delay or Skip Medical Care Due to Affordability, Access, and Negative Experiences

12 months ago talkbio0Tagged Access, Affordability, barriers, Delayed medical care, disparities, Experience, Gender, Health care facility, Healthcare equity, issues, Negative, Women 's healthcare

Women’s healthcare, Delayed medical care, Affordability issues, Access barriers, Negative healthcare experiences, Gender disparities in healthcare, Healthcare equity

Senator Sanders Investigates Skyrocketing Costs of Novo Nordisk’s Diabetes and Weight Loss Drugs

1 year ago talkbio0Tagged Affordability, Diabetes, Evaluation, Health care facility, Nordisk, Novos, Prices, Senator Bernie Sanders, Wegovy

Senator Bernie Sanders, Novo Nordisk, diabetes, weight loss, drug prices, Novos Ozempic, Wegovy, investigation, healthcare costs, affordability

Medicare Partially Covers Weight Loss Drugs Amidst High Price Concerns and Future Negotiation Prospects

1 year ago talkbio0Tagged accessibility, Administration occupational activities, Affordability, Increased, Mediation, Medicare, Obesity drugs, premium, Prices, semaglutide, utilization qualifier, Wegovy

Medicare, Obesity drugs, Wegovy, Semaglutide, Price negotiation, Affordability, Accessibility, Premium increases, Utilization management